BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Phase 4

• Conditions: Dystrophy, Retinal
• Interventions: Drug: Brolucizumab-Dbll

• Registration Number: NCT04690062
• Lead Sponsor: Benha University

Brief Summary

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Detailed Description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.

Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Study Timeline

• Study Start: 2020-10-25
• Status Verified: 2020-12
• Study First Submitted: 2020-12-21
• Study First Submitted QC: 2020-12-26
• Last Update Submitted: 2020-12-26
• Study First Posted: 2020-12-30
• Last Update Posted: 2020-12-30
• Primary Completion: 2022-12-25
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Dystrophy-Related macular neovascularization degeneration

Exclusion Criteria

• age related macular degeneration , other causes of macular neovascularization degeneration

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BEOVU	Brolucizumab-Dbll	Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity (BCVA)	12 months	Change in BCVA in LOG MARS(logarithm minimum angle of resolution)

Secondary Outcome Measures

Name	Time	Method
optical coherence tomography (OCT) foveal thickness	12 months	change in foveal thickness measured in micrometer

Trial Locations

Locations (1)

INMC; 🇦🇪 Abu Dhabi, United Arab Emirates